### <u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

#### **Materials**

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier	No, the study did not use antibodies	N/A
name, catalogue number and RRID, if available.		
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain.	No, the study did not use cell materials.	N/A
Provide accession number in repository <b>OR</b>		
supplier name, catalog number, clone number, OR RRID		
Primary cultures: Provide species, strain, sex of	No, the study did not use cell materials.	N/A
	No, the study did not use cell materials.	14/7
origin, genetic modification status.		
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,	No, the study did not use experimental animals.	N/A
genetic modification status. Provide accession		
number in repository <b>OR</b> supplier name, catalog		
number, clone number, <b>OR</b> RRID		
Animal observed in or captured from the	No, the study did not use experimental animals.	N/A
<b>field:</b> Provide species, sex and age where		
possible		
Model organisms: Provide Accession number	No, the study did not use experimental animals.	N/A
in repository (where relevant) <b>OR</b> RRID		
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession	No, the study did not involve plants.	N/A
number if available, and source (including location		
for collected wild specimens)		
Microbes: provide species and strain, unique	No, the study did not involve microbes.	N/A
accession number if available, and source		
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	No, there were no study participants.	N/A

## **Design**

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number <b>OR</b> cite DOI in manuscript.	No, the study was not clinical trials.	N/A
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step- by-step protocols are available.	Yes, See the section of Methods	
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done, <b>or</b> if they were not carried out.		
Sample size determination	No, the study did not involve this part	N/A
Randomisation	No, the study did not involve this part	N/A
Blinding	No, the study did not involve this part	N/A
Inclusion/exclusion criteria	Yes, See the "Tissue samples" in methods.	
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	No, the study did not involve this part of experiment.	N/A
Define whether data describe technical or biological replicates	No, the study did not involve this part of experiment.	N/A
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	No, not involved.	N/A
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	No, not involved.	N/A
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Yes. See the "Ethical Statement" and the attachment.	
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	No, this study is not subject to dual use research of concern.	N/A

# <u>Analysis</u>

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	Yes. See the paragraph of "LncRNA-mRNA microarrays" in methods.	

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of	Yes. See the paragraph of "LncRNA-mRNA microarrays"	
tests.	in methods.	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available,	Yes, datasets are available in supplemental attachment	
including protocols for access or restriction on access.		
If data are publicly available, provide accession	Yes. See the paragraph of "Identification of DEGs and	
number in repository or DOI or URL.	IncRNAs" in results.	
If publicly available data are reused, provide	Yes. See the section of Enrichr, ONCOMINE and GEPIA	
accession number in repository or DOI or URL, where possible.	database analysis in methods.	

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential		
for replicating the main findings of the study:		
State whether the code or software is available.	No, not involved.	N/A
If code is publicly available, provide accession	No, not involved.	N/A
number in repository, or DOI or URL.		

### Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article Information: http://dx.doi.org/10.21037/gs-21-151